Pub Date : 2023-09-01DOI: 10.3928/00485713-20230818-02
Kathryn K. Ridout, Erik R. Vanderlip, Samuel J. Ridout, Carol L. Alter
Measurement-based care is an evidence-based practice shown to improve patient outcomes in a variety of psychiatric disorders compared to usual care. Despite the evidence, measurement-based care is not routinely implemented in real-world clinical practice. This report uses an implementation science framework to review the literature regarding perceived barriers and facilitators to real-world measurement-based care implementation at the patient, clinician, organizational, and systems level. Further, we highlight the importance of treatment guideline implementation in parallel with measurement-based care, which helps ensure clinician action responsive to symptom measurement. [ Psychiatr Ann . 2023;53(9):405–409.]
{"title":"Measurement-Based Care Implementation Challenges and Opportunities in Real-World Practice","authors":"Kathryn K. Ridout, Erik R. Vanderlip, Samuel J. Ridout, Carol L. Alter","doi":"10.3928/00485713-20230818-02","DOIUrl":"https://doi.org/10.3928/00485713-20230818-02","url":null,"abstract":"Measurement-based care is an evidence-based practice shown to improve patient outcomes in a variety of psychiatric disorders compared to usual care. Despite the evidence, measurement-based care is not routinely implemented in real-world clinical practice. This report uses an implementation science framework to review the literature regarding perceived barriers and facilitators to real-world measurement-based care implementation at the patient, clinician, organizational, and systems level. Further, we highlight the importance of treatment guideline implementation in parallel with measurement-based care, which helps ensure clinician action responsive to symptom measurement. [ Psychiatr Ann . 2023;53(9):405–409.]","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135889099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230728-03
A. Nierenberg
{"title":"The Importance of Social Fitness for a Good Life","authors":"A. Nierenberg","doi":"10.3928/00485713-20230728-03","DOIUrl":"https://doi.org/10.3928/00485713-20230728-03","url":null,"abstract":"","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44233497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230719-01
P. K. Gillman, Vincent Van den Eynde
{"title":"MAOIs: Reconsideration and Re-education","authors":"P. K. Gillman, Vincent Van den Eynde","doi":"10.3928/00485713-20230719-01","DOIUrl":"https://doi.org/10.3928/00485713-20230719-01","url":null,"abstract":"","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46271448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230721-01
H. Unver, I. Turan
The coronavirus disease (COVID-19) pandemic has disrupted the lives of people around the world, causing illness, death, fear, and trauma. This study aims to determine the effect of fear of contracting COVID-19 on pregnancy stress and prenatal attachment in pregnant women. This cross-sectional and descriptive study was conducted with 270 pregnant women who were registered in the family health center of a city located in the eastern part of Turkey. Data were collected between November 2020 and March 2021. The average age of the participants was 28.24 ± 5.69. A positive and weak correlation was found between the Fear of COVID-19 Scale Mean score and the Prenatal Attachment Inventory (PAI) and Pregnancy Stress Rating Scale (PSRS) mean scores ( r = 0.379, 0.478; P < 0.001, respectively). In addition, a weak correlation was detected between the PAI mean score and the PSRS mean score ( r = 0.495; P < 0.001). Results showed that the fear of COVID-19 affected prenatal attachment at a proportion of 14% and pregnancy stress at a proportion of 22%. This study found that the fear of COVID-19 had effects on pregnancy stress and prenatal attachment. Healthcare professionals should consider the fear caused by the pandemic as a factor in the treatment-care and consultancy services provided to pregnant women in extraordinary, unprecedented times like the COVID-19 pandemic. [ Psychiatr Ann . 2023;53(8):381–388.]
{"title":"The Effect of Fear of COVID-19 on Prenatal Attachment and Pregnancy Stress in Pregnant Women","authors":"H. Unver, I. Turan","doi":"10.3928/00485713-20230721-01","DOIUrl":"https://doi.org/10.3928/00485713-20230721-01","url":null,"abstract":"\u0000 The coronavirus disease (COVID-19) pandemic has disrupted the lives of people around the world, causing illness, death, fear, and trauma. This study aims to determine the effect of fear of contracting COVID-19 on pregnancy stress and prenatal attachment in pregnant women. This cross-sectional and descriptive study was conducted with 270 pregnant women who were registered in the family health center of a city located in the eastern part of Turkey. Data were collected between November 2020 and March 2021. The average age of the participants was 28.24 ± 5.69. A positive and weak correlation was found between the Fear of COVID-19 Scale Mean score and the Prenatal Attachment Inventory (PAI) and Pregnancy Stress Rating Scale (PSRS) mean scores (\u0000 r\u0000 = 0.379, 0.478;\u0000 P\u0000 < 0.001, respectively). In addition, a weak correlation was detected between the PAI mean score and the PSRS mean score (\u0000 r\u0000 = 0.495;\u0000 P\u0000 < 0.001). Results showed that the fear of COVID-19 affected prenatal attachment at a proportion of 14% and pregnancy stress at a proportion of 22%. This study found that the fear of COVID-19 had effects on pregnancy stress and prenatal attachment. Healthcare professionals should consider the fear caused by the pandemic as a factor in the treatment-care and consultancy services provided to pregnant women in extraordinary, unprecedented times like the COVID-19 pandemic.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):381–388.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42264739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230717-01
Allan Young, J. Rucker, Vincent Van den Eynde, Charles Redhead, B. Barnett, Lila Godet, A. Cleare, John Cosgrove, S. Stahl, T. Birkenhäger, P. K. Gillman
Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed. [ Psychiatr Ann . 2023;53(8):359–363.]
{"title":"An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One","authors":"Allan Young, J. Rucker, Vincent Van den Eynde, Charles Redhead, B. Barnett, Lila Godet, A. Cleare, John Cosgrove, S. Stahl, T. Birkenhäger, P. K. Gillman","doi":"10.3928/00485713-20230717-01","DOIUrl":"https://doi.org/10.3928/00485713-20230717-01","url":null,"abstract":"\u0000 Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):359–363.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42104946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230713-01
S. Stahl, Vincent Van den Eynde, Lila Godet, Charles Redhead, P. K. Gillman
Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, necessitating exploration and understanding of potent but underutilized antidepressant options, such as classic monoamine oxidase inhibitors (MAOIs). This article presents a condensed overview of the fundamental principles outlined in the international consensus guideline on using MAOIs in TRD (the Prescriber's Guide), explicitly focusing on phenelzine and tranylcypromine. These drugs are powerful treatment options for severe depression, including atypical and melancholic subtypes, that have insufficiently responded to first- and second-line treatments. MAOIs are generally indicated before electroconvulsive therapy due to their favorable side-effect profile. However, several contraindications and drug interactions must be considered. This article aims to provide clinicians with a practical, accessible resource for implementing classic MAOIs in the management of TRD. [ Psychiatr Ann . 2023;53(8):347–352.]
{"title":"The Pocket Guide to Classic Monoamine Oxidase Inhibitors for Treatment-Resistant Depression","authors":"S. Stahl, Vincent Van den Eynde, Lila Godet, Charles Redhead, P. K. Gillman","doi":"10.3928/00485713-20230713-01","DOIUrl":"https://doi.org/10.3928/00485713-20230713-01","url":null,"abstract":"\u0000 Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, necessitating exploration and understanding of potent but underutilized antidepressant options, such as classic monoamine oxidase inhibitors (MAOIs). This article presents a condensed overview of the fundamental principles outlined in the international consensus guideline on using MAOIs in TRD (the Prescriber's Guide), explicitly focusing on phenelzine and tranylcypromine. These drugs are powerful treatment options for severe depression, including atypical and melancholic subtypes, that have insufficiently responded to first- and second-line treatments. MAOIs are generally indicated before electroconvulsive therapy due to their favorable side-effect profile. However, several contraindications and drug interactions must be considered. This article aims to provide clinicians with a practical, accessible resource for implementing classic MAOIs in the management of TRD.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):347–352.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44964310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230724-01
Mustafa Kavak, Meral Özkan
In recent years, the prevalence of obesity has been increasing. Obese patients can be treated with medication, diet, exercise, and bariatric surgery. Studies on bariatric surgery have mostly focused on the physiological aspect of the surgery, with little attention paid to its psychological effects. There are a limited number of national and international studies that investigate eating behaviors and depression after bariatric surgery together. This descriptive and correlational study aimed to determine the correlation between eating behaviors and depression levels of patients after bariatric surgery. The study was conducted at Fırat University Hospital General Surgery Outpatient Clinic between July 2018 and August 2019. The population of the study was 1,000 adult patients. The sample consisted of 278 patients determined by the power analysis. The Descriptive Characteristics Form was used to determine the descriptive characteristics of the patients, the Dutch Eating Behavior Questionnaire to determine the patients' eating behaviors, and the Beck Depression Inventory to determine their depression levels. Data was gathered through face-to-face interviews at least 1 month after the surgery. The data was assessed using percent distribution, arithmetic mean, and Pearson's correlation analysis. The eating behaviors of the participants were found to be high (104.38 ± 10.29), while their depression levels were low (17.87 ± 7.71). It was determined that there was a positive and weak correlation between the patients' eating behaviors and depression levels, which was statistically significant ( r = 0.190, P = 0.002). Consequently, it was determined that the eating behaviors of the patients improved, and their depression levels were low. Furthermore, as the patients' depression levels increased, so did their eating behaviors. To improve the mental health of patients after bariatric surgery, we must identify mental problems and develop solutions. We suggest that nurses plan training to help patients regulate their eating behaviors and reduce their depression levels. [ Psychiatr Ann . 2023;53(8):374–380.]
{"title":"The Correlation Between Eating Behaviors and Depression Levels After Bariatric Surgery","authors":"Mustafa Kavak, Meral Özkan","doi":"10.3928/00485713-20230724-01","DOIUrl":"https://doi.org/10.3928/00485713-20230724-01","url":null,"abstract":"\u0000 In recent years, the prevalence of obesity has been increasing. Obese patients can be treated with medication, diet, exercise, and bariatric surgery. Studies on bariatric surgery have mostly focused on the physiological aspect of the surgery, with little attention paid to its psychological effects. There are a limited number of national and international studies that investigate eating behaviors and depression after bariatric surgery together. This descriptive and correlational study aimed to determine the correlation between eating behaviors and depression levels of patients after bariatric surgery. The study was conducted at Fırat University Hospital General Surgery Outpatient Clinic between July 2018 and August 2019. The population of the study was 1,000 adult patients. The sample consisted of 278 patients determined by the power analysis. The Descriptive Characteristics Form was used to determine the descriptive characteristics of the patients, the Dutch Eating Behavior Questionnaire to determine the patients' eating behaviors, and the Beck Depression Inventory to determine their depression levels. Data was gathered through face-to-face interviews at least 1 month after the surgery. The data was assessed using percent distribution, arithmetic mean, and Pearson's correlation analysis. The eating behaviors of the participants were found to be high (104.38 ± 10.29), while their depression levels were low (17.87 ± 7.71). It was determined that there was a positive and weak correlation between the patients' eating behaviors and depression levels, which was statistically significant (\u0000 r\u0000 = 0.190,\u0000 P\u0000 = 0.002). Consequently, it was determined that the eating behaviors of the patients improved, and their depression levels were low. Furthermore, as the patients' depression levels increased, so did their eating behaviors. To improve the mental health of patients after bariatric surgery, we must identify mental problems and develop solutions. We suggest that nurses plan training to help patients regulate their eating behaviors and reduce their depression levels.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):374–380.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43333038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230713-02
P. K. Gillman, Vincent Van den Eynde, Lila Godet, Charles Redhead, A. Horwitz, Brian Barnett
This article describes and clarifies the two significant interactions encountered with monoamine oxidase inhibitors (MAOIs): serotonin toxicity and the tyramine pressor response. This is important because of the amount of inaccurate and misleading information (including in United States Food and Drug Administration-approved product information sheets and online resource and database systems) promulgated over the last few decades, which continues to cause confusion and undue concern. There are few if any clinically relevant CYP450 interactions with psychotropic drugs and no significant pharmacokinetic interactions. Serotonin toxicity is now well understood and only occurs in a problematic form when MAOIs are given in conjunction with serotonin reuptake inhibitors. Major prolonged elevations of blood pressure from tyramine are now less of a concern because of greatly reduced tyramine levels in foods. Therefore, MAOIs are safer and simpler to use in clinical practice than has usually been stated and should be considered earlier in the treatment algorithm for both atypical and melancholic depression. [ Psychiatr Ann . 2023;53(8):353–358.]
{"title":"Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions","authors":"P. K. Gillman, Vincent Van den Eynde, Lila Godet, Charles Redhead, A. Horwitz, Brian Barnett","doi":"10.3928/00485713-20230713-02","DOIUrl":"https://doi.org/10.3928/00485713-20230713-02","url":null,"abstract":"\u0000 This article describes and clarifies the two significant interactions encountered with monoamine oxidase inhibitors (MAOIs): serotonin toxicity and the tyramine pressor response. This is important because of the amount of inaccurate and misleading information (including in United States Food and Drug Administration-approved product information sheets and online resource and database systems) promulgated over the last few decades, which continues to cause confusion and undue concern. There are few if any clinically relevant CYP450 interactions with psychotropic drugs and no significant pharmacokinetic interactions. Serotonin toxicity is now well understood and only occurs in a problematic form when MAOIs are given in conjunction with serotonin reuptake inhibitors. Major prolonged elevations of blood pressure from tyramine are now less of a concern because of greatly reduced tyramine levels in foods. Therefore, MAOIs are safer and simpler to use in clinical practice than has usually been stated and should be considered earlier in the treatment algorithm for both atypical and melancholic depression.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):353–358.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49668469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.3928/00485713-20230718-01
M. Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, C. Andrade, T. Birkenhäger, J. Bodkin, David Nutt, B. Barnett, Simeon Shalom Feinberg, Gordon Parker, E. Ruhe, M. Fornaro, Charles Redhead, Lila Godet, P. K. Gillman
Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression. [ Psychiatr Ann . 2023;53(8):364–369.]
{"title":"An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two","authors":"M. Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, C. Andrade, T. Birkenhäger, J. Bodkin, David Nutt, B. Barnett, Simeon Shalom Feinberg, Gordon Parker, E. Ruhe, M. Fornaro, Charles Redhead, Lila Godet, P. K. Gillman","doi":"10.3928/00485713-20230718-01","DOIUrl":"https://doi.org/10.3928/00485713-20230718-01","url":null,"abstract":"\u0000 Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(8):364–369.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44152513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.3928/00485713-20230207-04
A. Okanlı, Merve İnan Budak, E. Yılmaz, Y. O. Ozdemir
The aim of this study was to evaluate the reliability and validity of the Turkish version of the Stigma Resistance Scale in patients with psychiatric disorders. This methodological study included 190 patients diagnosed with various psychiatric disorders in a psychiatry outpatient clinic of two hospitals in Turkey. The data were analyzed using SPSS and LISREL software. Explanatory and confirmatory factor analyses, Cronbach's alpha coefficients, and test-retest methods were used to determine the validity and reliability of the scale. The Cronbach's alpha coefficient of the scale was 0.89 for the entire scale and ranged between 0.72 and 0.82 for the five subscales; the item-total point correlations were between 0.43 and 0.63; and the correlation value of the test-retest was 0.78. The results of the explanatory factor analysis revealed that a five-factor structure, with factor loadings in the range of 0.44 to 0.70, explained 60.11% of the total variance. According to the results, acceptable adaptation values were computed (χ 2 /SD = 1.840, root-mean-square error of approximation = 0.06, standardized root-mean-square residuals = 0.070, comparative fit index = 0.96). In light of the findings, it was concluded that the Turkish version of the Stigma Resistance Scale could be used as a reliable and valid tool in assessing stigma resistance of Turkish psychiatric patients. Health care professionals may use this instrument in clinical practice to identify patients with mental illness who are experiencing stigma. [ Psychiatr Ann . 2023;53(7):333–339.]
{"title":"Stigma Resistance Scale: A Psychometric Study in a Turkish Mental Illness Sample","authors":"A. Okanlı, Merve İnan Budak, E. Yılmaz, Y. O. Ozdemir","doi":"10.3928/00485713-20230207-04","DOIUrl":"https://doi.org/10.3928/00485713-20230207-04","url":null,"abstract":"\u0000 The aim of this study was to evaluate the reliability and validity of the Turkish version of the Stigma Resistance Scale in patients with psychiatric disorders. This methodological study included 190 patients diagnosed with various psychiatric disorders in a psychiatry outpatient clinic of two hospitals in Turkey. The data were analyzed using SPSS and LISREL software. Explanatory and confirmatory factor analyses, Cronbach's alpha coefficients, and test-retest methods were used to determine the validity and reliability of the scale. The Cronbach's alpha coefficient of the scale was 0.89 for the entire scale and ranged between 0.72 and 0.82 for the five subscales; the item-total point correlations were between 0.43 and 0.63; and the correlation value of the test-retest was 0.78. The results of the explanatory factor analysis revealed that a five-factor structure, with factor loadings in the range of 0.44 to 0.70, explained 60.11% of the total variance. According to the results, acceptable adaptation values were computed (χ\u0000 \u0000 2\u0000 \u0000 /SD = 1.840, root-mean-square error of approximation = 0.06, standardized root-mean-square residuals = 0.070, comparative fit index = 0.96). In light of the findings, it was concluded that the Turkish version of the Stigma Resistance Scale could be used as a reliable and valid tool in assessing stigma resistance of Turkish psychiatric patients. Health care professionals may use this instrument in clinical practice to identify patients with mental illness who are experiencing stigma.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(7):333–339.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46969789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：